Update on Be Biopharma’s BE-101 Trial

NEW YORK, NY — June 18, 2026 — The Coalition for Hemophilia B (CHB), a national nonprofit that has served patients and their families affected by hemophilia B for more than 35 years, is sharing an update on the BE-101 clinical trial for our community.

Be Biopharma has ended its Phase 1/2 BeCoMe-9 study of BE-101, an investigational cell therapy for hemophilia B. According to a federal clinical trials database and confirmed by the company, the trial was discontinued as a strategic business decision and was not linked to any safety concern. The study had enrolled five of an anticipated 24 patients before it was halted.

BE-101 was being developed by Cambridge, Massachusetts–based Be Biopharma. The therapy used a patient’s own cells, modified outside the body to produce clotting factor IX (FIX), with the potential to be re-dosed if needed. The company has no other listed trials for BE-101.

The decision was tied to business and market factors rather than to the safety of the treatment. 

CHB will continue to follow developments across the hemophilia B research pipeline and keep the community informed as new information becomes available.

About the Coalition for Hemophilia B

The Coalition for Hemophilia B is a national nonprofit organization based in New York City. For more than 35 years, CHB has been dedicated to serving patients and their families affected by hemophilia B, providing patient programming, education, financial assistance, and advocacy nationwide. Learn more at hemob.org.